Skip to main content
EDAP
NASDAQ Industrial Applications And Services

EDAP TMS SA Reports Record Preliminary Q4 & FY2025 HIFU Revenue, Issues Strong 2026 Guidance

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$3.68
Mkt Cap
$137.603M
52W Low
$1.21
52W High
$4
Market data snapshot near publication time

summarizeSummary

EDAP TMS SA reported preliminary record HIFU revenue for Q4 and full-year 2025, fueled by strong system placements and procedure growth, and provided optimistic 2026 guidance for its core business.


check_boxKey Events

  • Record HIFU Revenue Reported

    EDAP TMS SA announced preliminary unaudited worldwide HIFU revenue between $12.9 million and $13.3 million for Q4 2025, marking the highest quarterly HIFU revenue in company history. Full-year 2025 HIFU revenue is expected to range from $36.7 million to $37.2 million, also a record.

  • Strong Operational Growth

    Performance was driven by a record 15 Focal One system placements during Q4 2025, contributing to a 69% annual year-over-year growth in Focal One system placements. U.S. Focal One HIFU procedures increased approximately 28% year-over-year in Q4.

  • Positive 2026 Revenue Guidance

    The company issued initial 2026 financial guidance, expecting core HIFU business revenue to be in the range of $50.0 million to $54.0 million, indicating significant continued growth. Combined non-core business revenue is projected between $22.0 million and $26.0 million.

  • Strategic Business Shift

    For the first time, the expected growth in HIFU revenue is anticipated to represent more than half of the company's total expected annual revenue, validating its execution strategy towards its core therapeutic ultrasound business.


auto_awesomeAnalysis

EDAP TMS SA announced preliminary record-breaking HIFU revenue for both the fourth quarter and full fiscal year 2025, driven by robust demand for its Focal One system and accelerating procedure growth. The company's core HIFU business is demonstrating significant momentum, with system placements and U.S. procedures showing strong year-over-year increases. The issued 2026 revenue guidance projects substantial continued growth for the HIFU segment, which is now expected to constitute over half of the company's total annual revenue. This strong performance and positive outlook for its primary growth driver are highly important for the company's valuation and future trajectory.

At the time of this filing, EDAP was trading at $3.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $137.6M. The 52-week trading range was $1.21 to $4.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EDAP - Latest Insights

EDAP
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
EDAP
Mar 25, 2026, 4:25 PM EDT
Filing Type: S-3
Importance Score:
9
EDAP
Mar 25, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
8
EDAP
Mar 25, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
EDAP
Mar 25, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
EDAP
Feb 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
EDAP
Jan 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8